EDTUTC-4 New YorkLog in Sign up

OCGN
Ocugen, Inc. Common Stock
stockNASDAQ

At CloseOct 23, 2026 3:59:55 PM EDT

0.74USD-6.481%(-0.05)8,585,243

Pre-marketOct 23, 2026 9:25:30 AM EDT

0.8099USD+2.519%(+0.0199)

After-hoursOct 23, 2026 4:58:30 PM EDT

0.749USD+1.381%(+0.01)

OCGN News

Day breaks

07:00 AM EDTOcugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4 ·

GlobeNewswire Inc.

06:36 AM EDTOcugen licenses retinitis pigmentosa gene therapy to MENA region ·

Investing.com

06:30 AM EDTOcugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa ·

GlobeNewswire Inc.

09:31 PM EDTOcugen CEO Shankar Musunuri sells $499,691 of company stock ·

Investing.com

02:49 PM EDTDid Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders? ·

PR Newswire

07:08 AM EDTOcugen appoints general manager for new European affiliate ·

Investing.com

07:02 AM EDTOcugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate ·

GlobeNewswire Inc.

10:15 AM EDTShort Interest Alert: Most and least shorted sub-$2B healthcare stocks in Sep. 2026 ·

Seeking Alpha

07:02 AM EDTOcugen to Participate in Upcoming Scientific Conferences ·

GlobeNewswire Inc.

07:02 AM EDTOcugen to Participate in Upcoming October Investor and Industry Conferences ·

GlobeNewswire Inc.

07:12 AM EDTOcugen receives provisional approval for gene therapy in Bahamas ·

Investing.com

07:02 AM EDTOcugen Receives Provisional Approval and Priority Designation Under the Longevity and Regenerative Therapies Act in The Bahamas to Provide OCU400 to Patients for Treatment of Retinitis Pigmentosa ·

GlobeNewswire Inc.

06:06 AM EDTOcugen stockholders approve adjournment of special meeting for share increase vote ·

Investing.com

07:02 AM EDTOcugen to Participate in Upcoming September Investor and Industry Conferences ·

GlobeNewswire Inc.